Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 15/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076742 | 1.00 | GCK (0.48) | GCKRARARARBTSHRMAPT | |
| SCHEMBL1107633 | 0.87 | GCK (0.50) | GCKRARARARBRARG | |
| SCHEMBL1107696 | 0.86 | GCK (0.62) | GCKRARARARBMAPTRAB9A | |
| SCHEMBL1107685 | 0.86 | GCK (0.62) | GCKRARARARBRARG | |
| SCHEMBL1107444 | 0.86 | GCK (0.62) | GCKRARARARBRARG | |
| SCHEMBL2086735 | 0.86 | GCK (0.62) | GCKRARARARBRARG | |
| SCHEMBL2175603 | 0.84 | GCK (0.47) | GCKRARARARBMAPTRARG | |
| SCHEMBL28558841 | 0.84 | TSHR (0.68) | TSHRMAPTRAB9APOLBNPC1 | |
| SCHEMBL1042436 | 0.83 | LMNA (0.54) | GCKRARARARBSMN1; SMN2 | |
| SCHEMBL2662217 | 0.83 | LMNA (0.54) | GCKRARARARBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093252-B2 | Crystalline polymorphic form of glucokinase activator | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| WO-2010092387-A1 | PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210841-A1 | CHEMICAL PROCESS 632 | F12, XDH, REN | GCK 2360/4885RARA 615/4885RARB 805/4885 |
| US-20100210621-A1 | CRYSTALLINE POLYMORPHIC FORM 631 | GCKR, GCK, HK1 | GCK 2/4885RARA 2320/4885RARB 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.